J. Reid

发表

A draft sequence of the rice genome (Oryza sativa L. ssp. japonica).

A. Oliphant, N. Tusneem, T. Macalma, 2002, Science.

A High Quality Draft Consensus Sequence of the Genome of a Heterozygous Grapevine Variety

Dustin A. Cartwright, M. Skolnick, B. Taillon, 2007, PloS one.

The genome of the domesticated apple (Malus × domestica Borkh.)

Roger E Bumgarner, S. Masiero, M. Skolnick, 2010, Nature Genetics.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

J. Cuzick, D. Berney, P. Scardino, 2011, The Lancet. Oncology.

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Sean V Tavtigian, Thomas Scholl, B. Ward, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

J. Reid, A. Lièvre, P. Laurent-Puig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IL23R R381Q and ATG16L1 T300A Are Strongly Associated With Crohn's Disease in a Study of New Zealand Caucasians With Inflammatory Bowel Disease

T. Merriman, A. Gutin, J. Reid, 2007, The American Journal of Gastroenterology.

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

William L. Welbourn, J. Reid, S. Freedland, 2014, International journal of urology : official journal of the Japanese Urological Association.

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

M. Rezai, P. Fasching, A. Schneeweiss, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation.

A. Gutin, J. Reid, T. Vyse, 2007, Human molecular genetics.

Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy.

William L. Welbourn, A. Gutin, J. Reid, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells

S. Steinberg, J. Reid, Kebin Liu, 2009, Journal of cellular and molecular medicine.

Prolaris: A novel genetic test for prostate cancer prognosis.

M. Cooperberg, P. Carroll, J. Cuzick, 2013 .

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy

G. Cancel-Tassin, O. Cussenot, J. Reid, 2018, World Journal of Urology.

A candidate prostate cancer susceptibility gene at chromosome 17p

Siavash Ghaffari, Alun Thomas, Nicola J. Camp, 2001, Nature Genetics.

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

J. Reid, S. Darb-Esfahani, J. Lanchbury, 2018, British Journal of Cancer.

Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer

L. Pusztai, A. Gutin, J. Reid, 2016, Clinical Cancer Research.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Z. Szallasi, G. Mills, E. Winer, 2016, Clinical Cancer Research.

Homologous Recombination De fi ciency ( HRD ) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Z. Szallasi, G. Mills, E. Winer, 2016 .

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

James M Ford, Victor Abkevich, Jafi A Lipson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes

Alexander Gutin, Victor Abkevich, Michael Perry, 2014, Breast Cancer Research.

BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer

B. Ward, D. Pruss, J. Reid, 2009, Cancer.

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

M. Cooperberg, P. Carroll, A. Gutin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.

A. Gutin, J. Reid, M. B. Warf, 2015, Biomarkers in medicine.

Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

Edward S. Kim, I. Wistuba, S. Swisher, 2013, Clinical Cancer Research.

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.

William L. Welbourn, J. Reid, Liang Cheng, 2016, Cancer biomarkers : section A of Disease markers.

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

D M Berney, J Cuzick, J. Cuzick, 2015, British Journal of Cancer.

Prevalence of BRCA1 and BRCA2 Mutations in Women with Breast Carcinoma In Situ and Referred for Genetic Testing

J. Reid, M. Hall, R. Wenstrup, 2010, Cancer Prevention Research.

Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

M. Rezai, P. Fasching, A. Schneeweiss, 2015 .

Homologous recombination deficiency score shows superior association with outcome compared with its individual score components in platinum-treated serous ovarian cancer

Robert Brown, A. Gutin, J. Reid, 2016 .

The predictive value of BRCA1 and BRCA2 mutation testing.

J. Reid, S. Neuhausen, T. Frank, 2000, Genetic testing.

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

J. Cuzick, D. Berney, P. Scardino, 2012, British Journal of Cancer.

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

William L. Welbourn, J. Bishoff, G. Sauter, 2014, The Journal of urology.

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

B. Ward, S. Tavtigian, D. Pruss, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.

G. Mills, A. Gutin, J. Reid, 2015 .

Abstract P3-06-11: Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer

Z. Szallasi, E. Winer, A. Richardson, 2015 .

Prediction of MLH1 and MSH2 mutations in Lynch syndrome.

Ewout W Steyerberg, Elena M Stoffel, Thomas Scholl, 2006, JAMA.

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.

J. Reid, M. Brawer, S. Stone, 2019, European urology.

Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance.

J. Cuzick, P. Scardino, E. Crawford, 2018, Urologic oncology.

Prognostic utility of biopsy‐derived cell cycle progression score in patients with National Comprehensive Cancer Network low‐risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance

J. Bishoff, T. Schlomm, J. Reid, 2017, BJU international.

Analytical Validation of a Cell Cycle Progression Signature Used as a Prognostic Marker in Prostate Cancer

J. Reid, H. Kimbrell, M. B. Warf, 2015 .

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

William L. Welbourn, A. Gutin, J. Reid, 2013, International journal of radiation oncology, biology, physics.

Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort.

M. Cooperberg, P. Carroll, J. Cuzick, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer

M. Rezai, P. Fasching, A. Schneeweiss, 2017 .

Analytical validation of a 12-gene molecular test for the prediction of distant recurrence in breast cancer

J. Reid, R. Kronenwett, M. B. Warf, 2017, Future science OA.

Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.

J. Cuzick, D. Berney, P. Scardino, 2015 .

Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy.

J. Reid, M. Radovich, K. Timms, 2018, JCO precision oncology.

Imaging , Diagnosis , Prognosis Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma

Edward S. Kim, I. Wistuba, S. Swisher, 2013 .

Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.

J. Cuzick, D. Berney, A. Gutin, 2011, Journal of Clinical Oncology.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

J. Reid, A. Lièvre, P. Laurent-Puig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort.

M. Cooperberg, P. Carroll, A. Gutin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

J. Cuzick, D. Berney, P. Scardino, 2011, The Lancet. Oncology.

Urological Survey Urological Oncology : Prostate Cancer Re : Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort

M. Cooperberg, A. Gutin, J. Reid, 2022 .

Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.

A. Gutin, J. Reid, M. B. Warf, 2015, Biomarkers in medicine.

Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)

J. Reid, S. Darb-Esfahani, J. Lanchbury, 2015 .

3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC)

G. Mills, Robert Brown, A. Gutin, 2016 .

Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy.

William L. Welbourn, A. Gutin, J. Reid, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.